Literature DB >> 28325865

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Kirsten Fischer1, Othman Al-Sawaf1, Anna-Maria Fink1, Mark Dixon2, Jasmin Bahlo1, Simon Warburton2, Thomas J Kipps3, Robert Weinkove4,5,6, Sue Robinson7, Till Seiler8, Stephen Opat9, Carolyn Owen10, Javier López11, Kathryn Humphrey2, Rod Humerickhouse12, Eugen Tausch13, Lukas Frenzel1, Barbara Eichhorst1, Clemens-M Wendtner1,14, Stephan Stilgenbauer13, Anton W Langerak15, Jacque J M van Dongen15, Sebastian Böttcher16, Matthias Ritgen16, Valentin Goede1, Mehrdad Mobasher17, Michael Hallek1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28325865      PMCID: PMC5437733          DOI: 10.1182/blood-2017-01-761973

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Authors:  John F Seymour; Shuo Ma; Danielle M Brander; Michael Y Choi; Jacqueline Barrientos; Matthew S Davids; Mary Ann Anderson; Anne W Beaven; Steven T Rosen; Constantine S Tam; Betty Prine; Suresh K Agarwal; Wijith Munasinghe; Ming Zhu; L Leanne Lash; Monali Desai; Elisa Cerri; Maria Verdugo; Su Young Kim; Rod A Humerickhouse; Gary B Gordon; Thomas J Kipps; Andrew W Roberts
Journal:  Lancet Oncol       Date:  2017-01-13       Impact factor: 41.316

Review 2.  Therapy of elderly/comorbid patients with chronic lymphocytic leukemia.

Authors:  Lukas Smolej
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

4.  Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

Authors:  John C Byrd; Joseph M Flynn; Thomas J Kipps; Michael Boxer; Kathryn S Kolibaba; David J Carlile; Guenter Fingerle-Rowson; Nicola Tyson; Jamie Hirata; Jeff P Sharman
Journal:  Blood       Date:  2015-10-15       Impact factor: 22.113

5.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

6.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Steven Coutre; John F Seymour; Talha Munir; Soham D Puvvada; Clemens-Martin Wendtner; Andrew W Roberts; Wojciech Jurczak; Stephen P Mulligan; Sebastian Böttcher; Mehrdad Mobasher; Ming Zhu; Monali Desai; Brenda Chyla; Maria Verdugo; Sari Heitner Enschede; Elisa Cerri; Rod Humerickhouse; Gary Gordon; Michael Hallek; William G Wierda
Journal:  Lancet Oncol       Date:  2016-05-10       Impact factor: 41.316

7.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

Authors:  Sebastian Böttcher; Matthias Ritgen; Kirsten Fischer; Stephan Stilgenbauer; Raymonde M Busch; Günter Fingerle-Rowson; Anna Maria Fink; Andreas Bühler; Thorsten Zenz; Michael Karl Wenger; Myriam Mendila; Clemens-Martin Wendtner; Barbara F Eichhorst; Hartmut Döhner; Michael J Hallek; Michael Kneba
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

8.  Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

Authors:  Gabor Kovacs; Sandra Robrecht; Anna Maria Fink; Jasmin Bahlo; Paula Cramer; Julia von Tresckow; Christian Maurer; Petra Langerbeins; Günter Fingerle-Rowson; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Stephan Stilgenbauer; Wolfram Klapper; Clemens-Martin Wendtner; Kirsten Fischer; Michael Hallek; Barbara Eichhorst; Sebastian Böttcher
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

9.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

  9 in total
  39 in total

Review 1.  Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies.

Authors:  Prioty Islam; Anthony R Mato
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Authors:  Matthew S Davids; Danielle M Brander; Haesook T Kim; Svitlana Tyekucheva; Jad Bsat; Alexandra Savell; Jeffrey M Hellman; Josie Bazemore; Karen Francoeur; Alvaro Alencar; Leyla Shune; Mohammad Omaira; Caron A Jacobson; Philippe Armand; Samuel Ng; Jennifer Crombie; Ann S LaCasce; Jon Arnason; Ephraim P Hochberg; Ronald W Takvorian; Jeremy S Abramson; David C Fisher; Jennifer R Brown
Journal:  Lancet Haematol       Date:  2019-06-14       Impact factor: 18.959

3.  A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Authors:  Anthony R Mato; Lindsey E Roeker; Toby A Eyre; Chadi Nabhan; Nicole Lamanna; Brian T Hill; Danielle M Brander; Paul M Barr; Frederick Lansigan; Bruce D Cheson; Arun K Singavi; Maryam Sarraf Yazdy; Nirav N Shah; John N Allan; Erica B Bhavsar; Joanna Rhodes; Kaitlin Kennard; Stephen J Schuster; AnnaLynn M Williams; Alan P Skarbnik; Andre H Goy; Julie M Goodfriend; Colleen Dorsey; Catherine C Coombs; Hande Tuncer; Chaitra S Ujjani; Ryan Jacobs; Allison M Winter; John M Pagel; Neil Bailey; Anna Schuh; Mazyar Shadman; Andrea Sitlinger; Hanna Weissbrot; Sivraj Muralikrishnan; Andrew Zelenetz; Amy A Kirkwood; Christopher P Fox
Journal:  Blood Adv       Date:  2019-05-28

Review 4.  On the architecture of translational research designed to control chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 5.  Selecting Frontline Therapy for CLL in 2018.

Authors:  Nitin Jain
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 6.  Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Authors:  Ciara L Freeman; Laurie Sehn
Journal:  Curr Oncol Rep       Date:  2018-11-27       Impact factor: 5.075

Review 7.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

8.  Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Authors:  Andrew W Roberts; Shuo Ma; Thomas J Kipps; Steven E Coutre; Matthew S Davids; Barbara Eichhorst; Michael Hallek; John C Byrd; Kathryn Humphrey; Lang Zhou; Brenda Chyla; Jacqueline Nielsen; Jalaja Potluri; Su Young Kim; Maria Verdugo; Stephan Stilgenbauer; William G Wierda; John F Seymour
Journal:  Blood       Date:  2019-04-25       Impact factor: 22.113

Review 9.  Targeting BCL-2 in Hematologic Malignancies.

Authors:  Nadia Khan; Brad Kahl
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

10.  Bendamustine plus rituximab in chronic lymphocytic leukemia: is there life in the old dog yet?

Authors:  Clemens-Martin Wendtner
Journal:  Haematologica       Date:  2018-04       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.